Background-Coronary vessel tone is modulated in part by ␤-adrenergic relaxation. However, the implication of specific ␤-adrenoceptor subtypes and their downstream vasorelaxing mechanism(s) in human coronary resistance arteries is poorly defined. ␤ 3 -Adrenoceptors were recently shown to vasodilate animal vessels and are expressed in human hearts. Methods and Results-We examined the expression and functional role of ␤ 3 -adrenoceptors in human coronary microarteries and their coupling to vasodilating nitric oxide (NO) and/or hyperpolarization mechanisms. The expression of ␤ 3 -adrenoceptor mRNA and protein was demonstrated in extracts of human coronary microarteries. Immunohistochemical analysis revealed their exclusive localization in the endothelium, with no staining of vascular smooth muscle.
T he existence of a rich sympathetic innervation of the coronary arteries raises the importance of catecholamines as endogenous modulators of myocardial perfusion, in addition to their direct inotropic effects. The increased oxygen demand after the latter is believed to be compensated by coronary vasodilation, in part through direct ␤-adrenergic relaxation of vascular smooth muscle. Classically, this has been ascribed to ␤ 1 -and ␤ 2 -adrenoceptor stimulation coupled to increases in smooth muscle cAMP. [1] [2] [3] However, in other large conductance or small resistance arteries, an additional vasorelaxing mechanism may operate through ␤ 2adrenoceptor activation of endothelial production of nitric oxide (NO). 4, 5 Although this pathway was shown to mediate the vasorelaxation of human forearm arteries with ␤-adrenergic agonists in vivo, 6 its existence in human coronary resistance arteries has received little attention thus far.
In nonvascular smooth muscle, such as in the colon or stomach, ␤-adrenergic agonists also elicit a relaxation through activation of an "atypical" ␤-adrenoceptor, more recently identified as the ␤ 3 -adrenoceptor. 7 Since its molecular identification, 8 the distribution and functional role of this receptor have been extended from the regulation of lipolysis in fat tissue 9 to modulation of cardiac contraction, 10 including in human ventricle. 11 In addition, we 12 and others 13, 14 observed a profound peripheral vasodilation after infusion of ␤ 3 -preferential agonists in the conscious dog, and recently, similar agonists were shown to elicit a NO-mediated relaxation of the rat aorta. 15, 16 This raised the possibility of a similar vasorelaxing mechanism in human coronary arteries. Because we previously observed an upregulation of ␤ 3adrenoceptor proteins in extracts of ischemic and dilated human hearts, 11 such a possibility would potentially pertain to our understanding of coronary vasoregulation in the diseased heart.
Endothelial cells modulate the vascular tone through both shear stress-and agonist-evoked release of vasorelaxants such as NO, prostacyclin, and (still incompletely characterized) endothelium-derived hyperpolarizing factor(s) (EDHF). The functional importance of the latter was suggested to be inversely correlated with vessel diameter 17, 18 and to be more prominent in circumstances of impaired NO-mediated vasorelaxation, such as that associated with risk factors for atherosclerosis and ischemic diseases. 19, 20 An EDHFmediated relaxation was observed in human resistance (including coronary) arteries in response to arachidonic acid 21 and adrenomedulin, 22 but the implication of EDHF in ␤-adrenergic vasodilation remained elusive.
In the present study, we therefore examined the putative expression and functional role of ␤ 3 -adrenoceptors in human coronary arterioles. We identified transcripts and proteins specific for ␤ 3 -adrenoceptors in the endothelium of these vessels, and their activation mediated an endotheliumdependent relaxation that involves both NO and vessel hyperpolarization.
Methods

Tissue Collection
Human right atrial and left ventricular tissue specimens obtained from patients undergoing cardiac surgery were placed in physiological saline solution (PSS) containing the following (mmol/L): NaCl 120, KCl 5.9, NaHCO 3 25, dextrose 17.5, CaCl 2 2.5, MgCl 2 1.2, NaH 2 PO 4 1.2 (pH 7.4), maintained at 0°C to 4°C, and carefully dissected to isolate microarteries. Coronary microarteries (70 to 170 m in diameter, 1 to 2 mm in length), rapidly cleaned of adherent connective tissue, were either kept at Ϫ80°C until homogenization or used for functional experiments.
Reverse Transcription-Polymerase Chain Reaction for mRNA Amplification
Human coronary microvessels were homogenized in GTC buffer (Tripure, Roche). After reverse transcription (RT), TaqMan polymerase chain reaction (PCR) was performed as described previously. 23 The Ct (threshold cycle) was defined as the cycle number at which the reporter fluorescence generated by cleavage of the probe crossed a fixed threshold above baseline. In the absence of template, its value was 39.9Ϯ0.08 (nϭ3), indicating negligible background fluorescence from the probes.
Specific primer and TaqMan probe sequences for the human ␤ 3 -adrenoceptor and human NOS3 (endothelial NO synthase [eNOS]) were designed as previously published. 23, 24 
Protein Immunoblotting
Microdissected vessels pooled from 6 to 9 atrial or ventricular specimens were ground in liquid nitrogen. Extracts were homogenized in 60 L of buffer (mmol/L: Tris-HCl 20 [pH 7.4], EDTA 2.5, NaCl 100, NaF 10, Na 3 VO 4 1, Na-deoxycholate 1%, SDS 0.1%, Triton X-100 1%, protease inhibitor cocktail). Protein samples were subjected to electrophoresis, transferred onto polyvinylidene difluoride membranes, and immunoblotted as described previously, 11 with antibodies directed against human ␤ 3 -adrenoceptors and eNOS.
Immunostaining of ␤ 3 -Adrenoceptors
Pieces of atrial appendages were embedded in TissueTek OCT compound (Sakura) and snap-frozen in precooled isopentane at Ϫ80°C. Prewashed fixed cryosections (5 m; 3.5% formaldehyde) were incubated with monoclonal anti-human ␤ 3 -adrenoceptor anti-bodies (1/200 in PBS with 1% BSA), then rinsed (PBS with 0.1% BSA) and incubated with secondary polyclonal rabbit anti-rat IgG (1/200) coupled to peroxidase. After they were washed, sections were counterstained with Mayer's hematoxylin and mounted for optical microscopy. Negative controls were performed in parallel where the primary antibody was omitted.
Videomotion Analysis of Vessel Contraction
Vessels were cannulated with dual glass micropipettes and secured with 10-0 nylon monofilament sutures in a Plexiglas isolated organ chamber circulated with oxygenated PSS (37°C) and placed on an inverted microscope (Axiovert S100, Zeiss) connected to a CCD camera. Microvessels were pressurized with a PSS-filled burette manometer at 60 mm Hg (a pressure chosen to avoid stretchdependent effects typically manifested at higher pressures) in a no-flow state. Digitized imaging (IONOPTIX Corporation) allowed continuous monitoring of vessel external diameter. All experiments were performed in the presence of a cyclooxygenase inhibitor (indomethacin, 10 mol/L). After 30 to 45 minutes of equilibration, vessels were contracted with high KCl solution (PSS, 50 mmol/L KCl replacing NaCl stoichiometrically). At the maximum contraction, vasorelaxation with substance P (100 nmol/L) was systematically tested to assess the presence of a functional endothelium. In some experiments the endothelium was selectively destroyed by an air bolus. All reagents were added in the bathing solution.
Measurement of Vessel Membrane Potential
Microvessels were mounted in an organ bath continuously circulated (6 mL/min) with oxygenated PSS at 37°C. All experiments were performed in the presence of a NOS inhibitor (L--nitroarginine, 100 mol/L) and indomethacin (10 mol/L).
After 60 minutes of equilibration, measurement of the smooth muscle membrane potential (Em) was made with a glass microelectrode (Clark, Electromedical Instruments, type GC 120F-15) filled with 1.5 mol/L KCl. The input resistance of the microelectrodes varied between 50 and 80 mol/L⍀. Differences in electric potential were measured with a Dagan amplifier (model 8100) and recorded. Criteria for a successful impalement were (1) an abrupt drop in voltage on entry of microelectrode into the cell, (2) stable membrane potential for at least 2 minutes, and (3) a sharp return to zero on withdrawal of the electrode.
Statistical Analysis
All results are expressed as meanϮSEM. Statistical comparisons were performed by use of Student t test or 1-way ANOVA when appropriate. Probability values Ͻ0.05 were considered significant.
Results
Patient Population
Clinical patient characteristics are summarized in the Table. Samples were obtained from patients undergoing cardiac transplantation (nϭ4) or other cardiac surgical procedures (nϭ60). Most patients suffered from ischemic cardiac diseases (76%). All were treated with a variable combination of drugs as detailed in the Table. The local ethics committee approved all tissue collections.
Endothelial-Restricted Expression of ␤ 3 -Adrenoceptors in Human Coronary Arterioles
An analysis of ␤ 3 -adrenoceptor and NOS3 mRNAs was performed by RT-PCR with the use of dissected arterioles from right auricular appendages. Amplimers for both transcripts were detected from 3 different preparations, with a mean Ct of 34.0Ϯ0.15 (PϽ0.0001 versus background; nϭ3) for ␤ 3adrenoceptors and 36.0Ϯ1.1 for NOS3 (Pϭ0.022 versus background; nϭ3). By comparison, the highly expressed housekeep-ing gene GAPDH generated detectable signals at a mean Ct of 26.0Ϯ0.26 when amplified from the same cDNAs. Figure 1 illustrates the identification of specific proteins with immunoaffinity for anti-human ␤ 3 -adrenoceptor anti-bodies in both Western blotting ( Figure 1A ) and immunohistochemistry ( Figure 1B) . Bands corresponding to ␤ 3adrenoceptors and eNOS were detected both in whole cardiac extracts from left ventricle and atria and in extracts of arterioles microdissected from the same tissues. In both cases, signals for ␤ 3 -adrenoceptors and eNOS are more intense in atrial versus ventricular extracts. To identify the specific cell type(s) expressing ␤ 3 -adrenoceptors, immunohistochemical analysis was performed in sections of human atrial myocardium. A positive staining was observed in cardiomyocytes, as previously described by us. 11 In addition, sections of arterioles stained positively ( Figure 1B 
␤ 3 -Adrenoceptors Mediate Relaxation of Human Coronary Arterioles
To assess the function of ␤ 3 -adrenoceptor signaling in the same vessels, variations of external diameter of preconstricted, pressurized human coronary microarterioles were studied by videomicroscopy with different ␤-adrenoceptor agonists. As illustrated by the typical experiment presented on Figure 2A , in vessels with an intact endothelium, the nonspecific ␤-agonist isoproterenol relaxed endothelin-1 (ET-1) preconstricted microarterioles by half. This relaxation was not affected on pretreatment with the ␤ 1 /␤ 2 -antagonist nadolol, thereby ruling out a ␤ 1 /␤ 2 -adrenoceptor-mediated effect, but was fully abrogated by the ␤ 1 /␤ 2 /␤ 3 -antagonist bupranolol, suggesting a ␤ 3 -adrenoceptor-mediated effect ( Figure 2B ). In support of the latter, the preferential ␤ 3adrenoceptor agonist BRL37344 produced a dose-dependent relaxation of the same amplitude ( Figure 2C ), and the maximum relaxation to BRL37344 was 52.3Ϯ13.2% of the ET-1 contraction (nϭ6). This relaxation was also resistant to nadolol (54.9Ϯ16.8%; nϭ5) but was fully abrogated by bupranolol (nϭ4; Figure 2D ). In coronary microarterioles with an intact endothelium pretreated with nadolol and phentolamine (combining ␣ 1 /␣ 2and ␤ 1 /␤ 2 -adrenoceptor blockade), norepinephrine (1 mol/L) also evoked a relaxation amounting to 41.4Ϯ7% (nϭ3) of ET-1 contraction (Figure 3 ).
Of note, the relaxation to BRL37344 was not observed in vessels that failed to relax to the endothelium-specific agonist substance P (not shown) or in which the endothelium was selectively destroyed, despite their full relaxation with sodium nitroprusside (a NO donor acting on the smooth muscle), confirming that the ␤ 3 -adrenoceptor response is dependent on a functional endothelium ( Figure  4A ). Conversely, these deendothelialized vessels exhibited a residual relaxation to isoproterenol (21.0Ϯ6.3%; nϭ6), which was inhibited by nadolol (1.4Ϯ0.5%; nϭ4) ( Figure  4B ). This identified an additional endotheliumindependent, ␤ 1 /␤ 2 -adrenergic response on the vascular smooth muscle. 
␤ 3 -Adrenoceptor-Mediated Relaxation Involves Both NO and an EDHF
To characterize the endothelial mediator for ␤ 3 -adrenoceptor relaxation, the effect of BRL37344 was first compared in vessels preconstricted with ET-1 or a high (50 mmol/L) KCl solution. The latter is known to depolarize the vessel membrane and prevent the relaxing effect of a (EDHF-like) hyperpolarizing factor. As shown in Figure 5A , although BRL37344 relaxed vessels preconstricted with both ET-1 and KCl, its relaxing effect was substantially reduced in vessels contracted with KCl (ET-1: 52.3Ϯ13.2% [nϭ6] versus KCl: 15.5Ϯ5.3% [nϭ4]), suggesting the participation of an EDHFlike response.
To determine the involvement of NO production in the KCl-resistant relaxation, similar experiments were performed in vessels preincubated with the NOS inhibitor L-nitroarginine. NOS inhibition abrogated the residual relaxation with BRL37344 in KCl-preconstricted vessels, confirming NOS involvement in the ␤ 3 -adrenoceptor response. Of note, the relaxing effect of BRL37344 on ET-1-preconstricted vessels was unaffected by NOS inhibition, suggesting compensation by the EDHF-like response ( Figure 5B ).
Two additional approaches were used to confirm the involvement of an EDHF-like response in the NOindependent ␤ 3 -adrenoceptor-mediated relaxation. First, we tested the effect of BRL37344 on the membrane potential of human arterioles mounted in the same conditions as for the relaxation assays. As illustrated in Figure 6A , acute application of BRL37344 in the presence of NOS and cyclooxygenase inhibition (to rule out confounding effects of NO and prostanoids) resulted in significant hyperpolarization. Sec-ond, the sensitivity of the BRL37344-mediated relaxation to the calcium-activated K ϩ channel inhibitors charybdotoxin and apamin was tested in similar vessels under videomicroscopy. As shown in Figure 6B , these inhibitors fully abrogated the residual relaxation, further confirming its mediation through an EDHF pathway.
Discussion
We characterized a novel pathway for the adrenergic vasorelaxation of human coronary microarteries through activation of ␤ 3 -adrenoceptors on endothelial cells. This is distinct from the vasodilation that follows activation of adenylyl cyclase and increases in cAMP, which are most often ascribed to ␤ 2 -adrenoceptor (and perhaps ␤ 1 -adrenoreceptor) activation in vascular smooth muscle cells. Indeed, our functional experiments with nonspecific ␤-adrenergic (as well as ␤ 3preferential) agonists demonstrate a vasorelaxation of human coronary microarteries with slow kinetics, similar to the smooth muscle relaxation attributed to the activation of atypical ␤-adrenoceptors in other tissues. The fact that this vasorelaxation was insensitive to nadolol (a ␤ 1 /␤ 2adrenoceptor antagonist) and was abrogated by bupranolol (a full ␤-antagonist) strongly supported a ␤ 3 -adrenoceptormediated response.
Accordingly, we provide evidence for the expression of mRNA and proteins of ␤ 3 -adrenoceptors in extracts of dissected cardiac microarterioles. We had successfully used the same molecular approaches to identify and quantify human ␤ 3 -adrenoceptors in whole human myocardium. 11 Using immunohistochemistry, we show that, in addition to cardiomyocytes, ␤ 3 -adrenoceptor expression is restricted to the endo- thelium of microarteries, with no staining of vascular smooth muscle. This is consistent with similar endothelium-restricted expression in rat aorta. 16 It would also account for the lack of ␤ 3 -adrenoceptor-mediated relaxation in vessels with dysfunctional or destroyed endothelium in which we failed to obtain a typical endothelial-mediated relaxation with substance P. Likewise, such response may have been undetected in previous studies in which human coronary microarteries from patients with end-stage heart failure and endothelial dysfunction were used, leaving only a residual smooth musclemediated ␤ 2 -adrenergic response. 3 Aside from prostanoids, NO and EDHF(s) account for the prototypical endothelium-mediated vasorelaxation. Consistent with the expression of eNOS in our vessels, we found the ␤ 3 -adrenoceptor relaxation to be mediated partly through NO production. This was evidenced by its complete abrogation by NOS inhibition under circumstances when both prostanoids and EDHF are inoperative (ie, after cyclooxygenase inhibition and preconstriction with high KCl, respectively). This also recapitulates our previous demonstration of a functional coupling of ␤ 3 -adrenoceptor agonists to NO production in whole human ventricular muscle through G ␣i proteins. 11 However, NOS inhibition had little (if any) effect on the vasorelaxation of vessels preconstricted with ET-1. This cannot be explained by incomplete NOS inhibition because similar treatment with L--nitroarginine abrogated the endothelium-dependent relaxation to substance P in the same vessels preconstricted with KCl (not shown). This strongly indicated the involvement of an alternative, EDHF-like response.
Although the precise nature of EDHF is still elusive, a consensus view is that this (these) factor(s) released from endothelial cells produces a hyperpolarization leading to vascular muscle relaxation through activation of calciumdependent K ϩ channels. 25 Our results in vessels constricted with high KCl solution (which modifies the electrochemical gradient for K ϩ ions, thereby preventing hyperpolarization) are in agreement with the participation of an EDHF. In addition, we directly demonstrated vessel hyperpolarization in response to ␤ 3 -adrenoceptor agonists and the abrogation of ␤ 3 -adrenoceptor-mediated relaxation after vessel pretreatment with the K ϩ channel inhibitors charybdotoxin and apamin, 2 signatures of an EDHF response. These results are also in agreement with the recent proposition of ␤ 3 -adrenoceptor-mediated relaxation through K ϩ channel activation in rat aorta. 16 Of note, the apparent insensitivity of the ␤ 3 relaxation to NOS inhibition in vessels preconstricted with ET-1 suggests that this EDHF response fully compensates for the absence of NO. Indeed, previous reports have suggested that EDHF acts as a backup relaxing mechanism in circumstances of endothelial NO-dependent dysfunction. 18, 20, 26 
Pathophysiological Implications
If our findings in isolated vessels truly reflect vasoregulation in vivo, our demonstration of a functional ␤ 3 -adrenoceptor vasorelaxation mediated in part by EDHF in human coronary resistance arteries may have a major bearing on the understanding of the regulation of coronary perfusion in circumstances such as dyslipidemia, diabetes, and atherosclerosis, all associated with decreased NO production and/or bioavailability. Indeed, previous work in human arteries suggested EDHF to be preserved despite the presence of risk factors for atherosclerosis (as is the case in the present study, in which we used arterioles mostly from ischemic patients). 18, 27 Notably, the natural catecholamine norepinephrine elicited similar ␤ 3 -adrenoceptor vasorelaxation, extending the relevance of our paradigm. Given the relative resistance of ␤ 3adrenoceptors to homologous desensitization, 28 their activation of such backup relaxation would seem particularly appropriate in circumstances of increased adrenergic tone, such as ischemia or heart failure, to preserve myocardial perfusion. Figure 6 . ␤ 3 -Agonist stimulation hyperpolarizes coronary microvessels; involvement of Ca 2ϩ -activated K ϩ channels. A, Typical recording showing the BRL37344-evoked hyperpolarization of smooth muscle cell membrane from isolated human coronary arteries. This tracing is representative of 5 similar experiments. B, Representative tracing of the contraction of a human coronary microarteriole with ET-1 after incubation with the NOS inhibitor L--nitroarginine and K ϩ channel inhibitors charybdotoxin and apamin (100 mol/L each). Under these conditions, no residual relaxation is observed in response to the ␤ 3 -agonist BRL37344. This tracing is representative of 3 similar experiments.
